Vaxart, Inc. 8-K

What Happened

• On May 19, 2026, Vaxart, Inc. filed an 8-K announcing it issued a letter and press release to shareholders highlighting the company’s clinical and operational progress, strategic priorities and commitment to long‑term value creation. The company urged shareholders to support the six director nominees nominated by Vaxart’s Board and addressed a shareholder nomination of three dissident candidates.
• Vaxart stated its Annual Meeting of Stockholders is scheduled for July 16, 2026 and filed preliminary proxy materials with the SEC the same day. Shareholders are directed to Vote.Vaxart.com for more information.

Key Details

• Filing date: May 19, 2026 (Form 8-K, Item 8.01).
• Annual Meeting date: July 16, 2026.
• Board nominees: Company is backing six director nominees; a shareholder has nominated three dissident candidates.
• Deadlines: Shareholder proposals under Rule 14a‑8 and universal‑proxy notice and related information required by Rule 14a‑19 must be received by Vaxart’s Corporate Secretary no later than 5:00 p.m. ET on May 29, 2026. Proposals/notice to be sent to 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (or emailed to the Corporate Secretary).

Why It Matters

• The 8‑K starts the formal proxy process for Vaxart’s 2026 Annual Meeting and sets firm deadlines for shareholder proposals and alternative‑slate proxy solicitations. Shareholders will vote on board composition at the July 16 meeting, and the company’s communications frame its case for supporting the incumbent slate. Investors should note the timelines and review the company’s proxy materials (and any dissident materials) before voting.